Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 1817 results
June 2019
-
Media ReleaseLong-term survival benefit shown for metastatic melanoma patients treated with Novartis Tafinlar® + Mekinist®Five-year Tafinlar + Mekinist survival data presented at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting and published simultaneously in The New England Journal of Medicine…
-
Toward improving the health and longevity of transplanted organs
Novartis researchers are working to extend the life of organ transplants
-
Media ReleaseNovartis Shows Growing Strength in Lung Cancer Innovation with New Capmatinib Investigational Data and Novel Canakinumab Clinical TrialsPrimary analysis of investigational capmatinib (INC280) in the GEOMETRY mono-1 study demonstrates promising efficacy in patients with locally advanced or metastatic non-small cell lung cancer (…
-
Media ReleaseXolair® (omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studiesIn the phase III POLYP 1 and POLYP 2 studies, omalizumab met both co-primary endpoints and key secondary endpoints in adults with chronic rhinosinusitis with nasal polyps (CRSwNP) with inadequate…
-
Media ReleaseNovartis Kisqali significantly extends life in women with HR+/HER2- advanced breast cancer in MONALEESA-7 trialKisqali is the only CDK4/6 inhibitor to show superior overall survival in advanced breast cancer (HR=0.712; p=0.00973)[1] After a median of 42 months follow-up, the survival rate was 70.2% for…
May 2019
-
Media ReleaseNovartis' phase III QUARTZ study of new investigational inhaled combination treatment QMF149 meets primary and key secondary endpoints in patients with inadequately controlled asthmaLow dose QMF149 (indacaterol acetate and mometasone furoate) demonstrated both statistically significant and clinically meaningful improvements in lung function and asthma control compared to…
-
Women in Science: Shannon Campbell
How Shannon Campbell, Senior Vice President & Franchise Head at Novartis Oncology, came into her current role and leadership position.
-
Investigating the myopia mystery
Two scientists from Basel are trying to shed light on why myopia is impacting more and more people.
-
Key ReleaseFDA approves Novartis Piqray® - the first and only treatment specifically for patients with a PIK3CA mutation in HR+/HER2- advanced breast cancerPiqray (alpelisib, formerly BYL719) plus fulvestrant nearly doubled median PFS (11.0 vs 5.7 months) in HR+/HER2- advanced breast cancer patients with a PIK3CA mutation compared to fulvestrant alone…
-
Key ReleaseAveXis Announces Innovative Zolgensma® Gene Therapy Access Programs for US Payers and FamiliesOne-time treatment with Zolgensma (onasemnogene abeparvovec-xioi) is designed to replace lifetime of chronic therapy for all pediatric patients with SMA Annualized cost of Zolgensma is USD…
-
Key ReleaseAveXis receives FDA approval for Zolgensma®, the first and only gene therapy for pediatric patients with spinal muscular atrophy (SMA)SMA is a rare genetic disease that leads to progressive muscle weakness, paralysis and, when left untreated in its most severe form, permanent ventilation or death for most patients by age 2[1],[2…
-
Cancer research drives breast cancer treatment forward
Novartis team perseveres to develop more personalized approach to breast cancer therapy.
Pagination
- ‹ Previous page
- 1
- …
- 69
- 70
- 71
- 72
- 73
- 74
- 75
- …
- 152
- › Next page